Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion
- Global revenues of $3.9 billion, reflect an increase of 7% from the third quarter of 2022
- Increased revenues reflect sustained growth of AUSTEDO®, AJOVY® and global generics business:
- Growth of AUSTEDO in North America
- Growth of AJOVY globally
- Stable and sustainable generics business in the U.S.; continued growth in Europe and International Markets
- GAAP diluted EPS of $0.07
- Non-GAAP diluted EPS of $0.60
- Cash flow generated from operating activities of $5 million
- Free cash flow of $229 million
- Exclusive collaboration with Sanofi on Anti TL1-A (TEV-‘574) entered into in October 2023 (PR)
- Olanzapine LAI (TEV-‘749) Phase 3 results accelerated; now expected in the second half of 2024
- Teva api new CEO and management team announced (PR)
- 2023 revenues outlook revised to $15.1-$15.5 billion from $15.0-$15.4 billion; all other key components reaffirmed:
- Non-GAAP operating Income of $4.0 - $4.4 billion
- Adjusted EBITDA of $4.5 - $4.9 billion
- Non-GAAP diluted EPS of $2.25 - $2.55
- Free cash flow of $1.7 - $2.1 billion
TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2023.
View the Highlights: Q3 2023 Business Results Infographic
Mr. Richard Francis, Teva's President and CEO, commenting on the war in Israel, said: "Following the terror attacks in Israel on October 7, 2023, Teva’s Board, leadership team, and I have made the safety of our Israeli employees our utmost priority. As a company with deep roots in Israel, we are humbled by the incredible resilience, care and resolve being shown in delivering our medicines to the millions of patients around the world who count on us. Currently, our production remains largely unaffected, and we have increased our emergency medical supplies, product donations and other supporting activities."
Commenting on Teva's results for the third quarter of 2023, Mr. Francis said: "In Q3 2023, Teva delivered strong financial and business results, with revenues increasing by 7% compared to Q3 2022, to a total of $3.9 billion. Continued solid performance of AUSTEDO, AJOVY and our generics business delivered growth across all geographies. Based on these strong and consistent results, we are increasing our revenue outlook for 2023 for the second consecutive quarter."
Mr. Francis continued, "Over the six months since our Pivot to Growth strategy was launched, we made significant progress in executing on all four pillars, as well as realizing our goal of becoming a stronger, bolder and simpler organization. Last month, we announced an exclusive collaboration with Sanofi for our promising Anti TL1-A asset, leveraging the innovative R&D and commercial expertise of both companies. We have accelerated our olanzapine LAI progress, with Phase 3 results now expected in the second half of 2024. In addition, we are on track to reach our 2023 growth targets through continued optimization of sales and marketing efforts. In our generics business, we are focusing our portfolio on high value complex products and optimizing our network. We are advancing toward Teva api becoming a stand-alone unit, and we are announcing the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of Teva api."
Pivot to Growth Strategy
In May 2023, we introduced our new “Pivot to Growth” strategy, which is based on four key pillars: (i) delivering on our growth engines, mainly AUSTEDO, AJOVY, UZEDYTM and our late-stage pipeline of biosimilars; (ii) stepping up innovation through delivering on our late-stage innovative pipeline assets as well as building up our early-stage pipeline organically and potentially through business development activities; (iii) sustaining our generics medicines powerhouse with a global commercial footprint, focused portfolio, pipeline and manufacturing footprint; and (iv) focusing our business by optimizing our portfolio and global manufacturing footprint to enable strategic capital deployment to accelerate our near and long-term growth engines and reorganizing certain of our business units to a more optimal structure, while also reorganizing key business units to enhance operational efficiency.
Third Quarter 2023 Consolidated Results
Revenues in the third quarter of 2023 were $3,850 million, an increase of 7% in both U.S. dollars and local currency terms compared to the third quarter of 2022. This increase was mainly due to higher revenues from generic products in all our segments, AUSTEDO in our North America segment and AJOVY in all our segments, partially offset by lower revenues from BENDEKA and TREANDA in our North America segment as well as from API sales to third parties.
Exchange rate movements during the third quarter of 2023, net of hedging effects, negatively impacted our revenues by $9 million, compared to the third quarter of 2022. Exchange rate movements during the third quarter of 2023, including hedging effects, negatively impacted our operating income and non-GAAP operating income by $53 million and $51 million, respectively, compared to the third quarter of 2022.
Gross profit in the third quarter of 2023 was $1,851 million, an increase of 11% compared to $1,669 million in the third quarter of 2022. Gross profit margin was 48.1% in the third quarter of 2023, compared to 46.4% in the third quarter of 2022. Non-GAAP gross profit was $2,060 million in the third quarter of 2023, an increase of 8% compared to the third quarter of 2022. Non-GAAP gross profit margin was 53.5% in the third quarter of 2023, compared to 53.0% in the third quarter of 2022. The increase in both gross profit margin and non-GAAP gross profit margin was mainly due to a favorable mix of products in our North America segment primarily driven by an increase in revenues from AUSTEDO, partially offset by higher costs due to inflationary and other macroeconomic pressures.
Research and Development (R&D) expenses in the third quarter of 2023 were $253 million, an increase of 44% compared to $175 million in the third quarter of 2022 as we continue to execute on our Pivot to Growth Strategy. Our higher R&D expenses in the third quarter of 2023, compared to the third quarter of 2022, were mainly due to an increase related to our late-stage innovative pipeline in neuroscience (mainly neuropsychiatry), in immunology and immuno-oncology. In addition, in the third quarter of 2022 our R&D expenses were lower due to an adjustment in payments pursuant to a contract with one of our R&D partners.
Selling and Marketing (S&M) expenses in the third quarter of 2023 were $576 million, an increase of 7% compared to the third quarter of 2022.
General and Administrative (G&A) expenses in the third quarter of 2023 were $268 million, a decrease of 5% compared to the third quarter of 2022.
Other income in the third quarter of 2023 was $9 million, compared to $2 million in the third quarter of 2022.
Operating income in the third quarter of 2023 was $355 million, compared to an operating income of $419 million in the third quarter of 2022. Operating income as a percentage of revenues was 9.2% in the third quarter of 2023, compared to 11.6% in the third quarter of 2022. The lower operating income in the third quarter of 2023 was mainly due to higher legal settlements and loss contingencies, higher R&D and S&M expenses in the third quarter of 2023, partially offset by higher gross profit in the third quarter of 2023. Non-GAAP operating income in the third quarter of 2023 was $1,020 million representing a non-GAAP operating margin of 26.5% compared to non-GAAP operating income of $977 million representing a non-GAAP operating margin of 27.2% in the third quarter of 2022. The decrease in non-GAAP operating margin in the third quarter of 2023 was mainly impacted by an increase in R&D expenses, partially offset by higher non-GAAP gross profit margin, as discussed above, as well as lower G&A expenses.
Adjusted EBITDA was $1,134 million in the third quarter of 2023, an increase of 4%, compared to $1,089 million in the third quarter of 2022.
Financial expenses, net in the third quarter of 2023 were $280, mainly comprised of net-interest expenses of $247 million and a negative exchange rate impact driven mainly from currencies which we were unable to hedge. In the third quarter of 2022, financial expenses were $252 million, mainly comprised of net-interest expenses of $229 million.
In the third quarter of 2023, we recognized a tax benefit of $12 million, on a pre-tax income of $75 million. In the third quarter of 2022, we recognized a tax expense of $107 million, on a pre-tax income of $166 million. Our tax rate for the third quarter of 2023 was mainly affected by deferred tax benefits resulting from intellectual property related integration plans. Such integration plans have been adopted, among others, in an effort to address the global adoption of the Organization for Economic Co-operation and Development (OECD) Pillar Two minimum effective corporate tax, commencing in 2024.
Non-GAAP tax rate in the third quarter of 2023 was 9%, compared to 10% in the third quarter of 2022. Our non-GAAP tax rate in the third quarter of 2023 was mainly affected by the generation of profits in various jurisdictions with different tax rates, tax benefits in Israel and other countries, deferred tax benefits resulting from intellectual property related integration plans, as well as infrequent or non-recurring items. Our non-GAAP tax rate in the third quarter of 2022 was mainly affected by the mix of products we sold, interest expense disallowances and adjustments to valuation allowances on deferred tax assets.
We expect our annual non-GAAPtax rate for 2023 to be between 12%-15%, higher than our non-GAAP tax rate for 2022, which was 12%, mainly due to the effect of a portion of the realization of losses related to an investment in one of our U.S. subsidiaries in 2022.
Net income attributable to Teva and diluted earnings per share in the third quarter of 2023 were $80 million and $0.07, respectively, compared to $56 million and $0.05, respectively, in the third quarter of 2022. The higher net income in the third quarter of 2023 was mainly due to the tax benefit in 2023 and tax expense in 2022, partially offset by lower operating income, as discussed above. Non-GAAP net income attributable to Teva and non-GAAP diluted earnings per share in the third quarter of 2023 were $677 million and $0.60, respectively, compared to $658 million and $0.59, respectively, in the third quarter of 2022.
As of September 30, 2023 and 2022, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,157 million and 1,144 million, respectively.
Non-GAAP information: net non-GAAP adjustments in the third quarter of 2023 were $598 million. Non-GAAP net income attributable to Teva and non-GAAP diluted EPS for the third quarter of 2023 were adjusted to exclude the following items:
- Amortization of purchased intangible assets of $145 million, of which $130 million is included in cost of sales and the remaining $15 million in S&M expenses;
- Impairment of long-lived assets of $48 million;
- Legal settlements and loss contingencies of $314 million;
- Contingent consideration expenses of $16 million;
- Equity compensation expenses of $31 million;
- Restructuring expenses of $27 million;
- Accelerated depreciation of $25 million;
- Financial expenses of $14 million;
- Costs related to regulatory actions taken in facilities of $1 million;
- Gain on sale of business of $5 million;
- Other non-GAAP items of $63 million;
- Items attributable to non-controlling interests of $1 million; and
- Corresponding tax effects and unusual tax items of $80 million.
We believe that excluding such items facilitates investors’ understanding of our business including underlying performance trends, thereby improving the comparability of our business performance results between reporting periods.
For further information, see the tables below for a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and the information under “Non-GAAP Financial Measures.” Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP.
Cash flow generated from operating activities during the third quarter of 2023 was $5 million, compared to $543 million in the third quarter of 2022. The lower cash flow generated in the third quarter of 2023 resulted mainly from changes in working capital items, including a negative impact from accounts receivables, net of SR&A, higher inventory levels, and higher legal payments, partially offset by a positive impact from accounts payables.
During the third quarter of 2023, we generated free cash flow of $229 million, which we define as comprising $5 million in cash flow generated from operating activities, $362 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $10 million in proceeds from divestitures of businesses and other assets, partially offset by $149 million in cash used for capital investment. During the third quarter of 2022, we generated free cash flow of $685 million, which we define as comprising $543 million in cash flow generated from operating activities, $262 million in beneficial interest collected in exchange for securitized accounts receivables and $2 million in proceeds from divestitures of businesses and other assets, partially offset by $122 million in cash used for capital investment. The decrease in the third quarter of 2023, resulted mainly from lower cash flow generated from operating activities as explained above.
As of September 30, 2023, our debt was $19,974 million, compared to $21,212 million as of December 31, 2022. This decrease was mainly due to $1,646 million senior notes repaid at maturity and $54 million of exchange rate fluctuations, partially offset by $500 million outstanding under our $1.8 billion unsecured syndicated sustainability-linked revolving credit facility, entered into in April 2022, as amended in February 2023 (“RCF”). Additionally, during the first quarter of 2023, we repurchased $2,506 million aggregate principal amount of notes upon consummation of a cash tender offer, and issued $2,445 million of sustainability-linked senior notes net of issuance costs. In July 2023, a total amount of $700 million was withdrawn under the RCF, of which $200 million was repaid in September 2023. As of September 30, 2023 and as of the date of this Press Release, $500 million is outstanding under the RCF. The portion of total debt classified as short-term as of September 30, 2023 was 7% compared to 10% as of December 31, 2022. Our average debt maturity was approximately 6.1 years as of September 30, 2023, compared to 5.8 years as of December 31, 2022.
In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of this Press Release, the situation is evolving. Israel is included in Teva’s International Markets segment results. Teva’s global headquarters and several manufacturing and R&D facilities are located in Israel. Currently, such activities in Israel remain largely unaffected. Teva continues to maintain contingency plans with backup production locations for key products. As of the date of this Press Release, the impact of the war on Teva’s results of operations and financial condition is immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of such war.
Segment Results for the Third Quarter of 2023
North America Segment
Our North America segment includes the United States and Canada. As part of a recent shift in executive management responsibilities, commencing January 1, 2024, Canada will be reported as part of our International Markets segment.
The following table presents revenues, expenses and profit for our North America segment for the three months ended September 30, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
Three months ended September 30, |
|||||
|
|
2023 |
|
2022 |
|||
|
|
(U.S. $ in millions / % of Segment Revenues) |
|||||
|
Revenues |
$ |
2,002 |
100% |
$ |
1,809 |
100% |
|
Gross profit |
|
1,093 |
54.6% |
|
942 |
52.1% |
|
R&D expenses |
|
163 |
8.1% |
|
111 |
6.1% |
|
S&M expenses |
|
257 |
12.8% |
|
232 |
12.8% |
|
G&A expenses |
|
98 |
4.9% |
|
122 |
6.8% |
|
Other income |
|
(2) |
§ |
|
§ |
§ |
|
Segment profit* |
$ |
577 |
28.8% |
$ |
477 |
26.3% |
|
|
|
|
|
|
|
|
|
* Segment profit does not include amortization and certain other items. |
||||||
Revenues from our North America segment in the third quarter of 2023 were $2,002 million, an increase of $193 million, or 11%, compared to the third quarter of 2022. This increase was mainly due to higher revenues from generic products and certain innovative products, primarily AUSTEDO and AJOVY, partially offset by lower revenues from BENDEKA and TREANDA.
Revenues in the United States, our largest market, were $1,898 million in the third quarter of 2023, an increase of $125 million or 7% compared to the third quarter of 2022.
Revenues by Major Products and Activities
The following table presents revenues for our North America segment by major products and activities for the three months ended September 30, 2023 and 2022:
|
|
|
|
|
|
||||||
|
|
|
Three months ended |
|
Percentage |
||||||
|
|
|
2023 |
|
2022 |
|
2023-2022 |
||||
|
|
|
(U.S. $ in millions) |
|
|
||||||
|
|
|
|
|
|
|
|
|
|
||
|
Generic products |
|
$ |
929 |
|
$ |
806 |
|
15% |
||
|
AJOVY |
|
|
61 |
|
|
57 |
|
8% |
||
|
AUSTEDO |
|
|
339 |
|
|
260 |
|
30% |
||
|
BENDEKA and TREANDA |
|
|
57 |
|
|
77 |
|
(26%) |
||
|
COPAXONE® |
|
|
103 |
|
|
105 |
|
(2%) |
||
|
Anda |
|
|
367 |
|
|
371 |
|
(1%) |
||
|
Other* |
|
|
146 |
|
|
133 |
|
10% |
||
|
Total |
|
$ |
2,002 |
|
$ |
1,809 |
|
11% |
||
|
|
|
|
|
|
|
|
|
|
||
* Other revenues in the third quarter of 2023 increased mainly due to a reduction in estimated liabilities in connection with ProAir® HFA following its discontinuation on October 1, 2022.
Generic products revenues in our North America segment (including biosimilars) in the third quarter of 2023 were $929 million, an increase of 15% compared to the third quarter of 2022, mainly due to revenues from lenalidomide capsules (the generic version of Revlimid®), partially offset by increased competition to other generic products.
In the third quarter of 2023, our total prescriptions were approximately 320 million (based on trailing twelve months), representing 8.4% of total U.S. generic prescriptions, compared to approximately 302 million (based on trailing twelve months), representing 8.2% of total U.S. generic prescriptions in the third quarter of 2022, all according to IQVIA data.
AJOVY revenues in our North America segment in the third quarter of 2023 increased by 8% to $61 million, compared to the third quarter of 2022, mainly due to growth in volume. In the third quarter of 2023, AJOVY’s exit market share in the United States in terms of total number of prescriptions was 24.9% compared to 24.7% in the third quarter of 2022.
AUSTEDO revenues in our North America segment in the third quarter of 2023 increased by 30%, to $339 million, compared to $260 million in the third quarter of 2022, mainly due to growth in volume with the launch of AUSTEDO XR in May 2023.
AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023, and became commercially available in the U.S. in May 2023. AUSTEDO XR is a new once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington’s disease, additional to the currently marketed twice-daily AUSTEDO. AUSTEDO XR is protected by nine Orange Book patents expiring between 2031 and 2041.
UZEDY (risperidone) extended-release injectable suspension was approved by the FDA on April 28, 2023 for the treatment of schizophrenia in adults, and was launched in the U.S. in May 2023. UZEDY is the first subcutaneous, long-acting formulation of risperidone that controls the steady release of risperidone. UZEDY is protected by nine Orange Book patents expiring between 2025 and 2033.
BENDEKA and TREANDA combined revenues in our North America segment in the third quarter of 2023 decreased by 26% to $57 million, compared to the third quarter of 2022, mainly due to generic bendamustine products entry into the market. The orphan drug exclusivity that had attached to bendamustine products expired in December 2022.
COPAXONE revenues in our North America segment in the third quarter of 2023 decreased by 2% to $103 million, compared to the third quarter of 2022, mainly due to generic competition in the United States and a decrease in glatiramer acetate market share due to availability of alternative therapies. COPAXONE revenues in the third quarter of 2023 were also positively impacted by a reduction in sales allowance.
Anda revenues from third-party products in our North America segment in the third quarter of 2023 decreased by 1% to $367 million, compared to $371 million in the third quarter of 2022, mainly due to lower demand.
North America Gross Profit
Gross profit from our North America segment in the third quarter of 2023 was $1,093 million, an increase of 16%, compared to $942 million in the third quarter of 2022.
Gross profit margin for our North America segment in the third quarter of 2023 increased to 54.6%, compared to 52.1% in the third quarter of 2022. This increase was mainly due to a favorable mix of products primarily driven by an increase in revenues from AUSTEDO.
North America Profit
Profit from our North America segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.
Profit from our North America segment in the third quarter of 2023 was $577 million, an increase of 21% compared to $477 million in the third quarter of 2022. This increase was mainly due to higher gross profit, partially offset by higher R&D expenses.
Europe Segment
Our Europe segment includes the European Union, the United Kingdom and certain other European countries.
The following table presents revenues, expenses and profit for our Europe segment for the three months ended September 30, 2023 and 2022:
|
|
Three months ended September 30, |
|||||
|
|
2023 |
|
2022 |
|||
|
|
(U.S. $ in millions / % of Segment Revenues) |
|||||
|
Revenues |
$ |
1,146 |
100% |
$ |
1,069 |
100% |
|
Gross profit |
|
648 |
56.6% |
|
634 |
59.3% |
|
R&D expenses |
|
62 |
5.4% |
|
44 |
4.1% |
|
S&M expenses |
|
184 |
16.0% |
|
169 |
15.8% |
|
G&A expenses |
|
66 |
5.7% |
|
61 |
5.7% |
|
Other income |
|
§ |
§ |
|
§ |
§ |
|
Segment profit* |
$ |
338 |
29.5% |
$ |
360 |
33.7% |
|
___________ |
|
|
|
|
|
|
|
* Segment profit does not include amortization and certain other items. |
||||||
Revenues from our Europe segment in the third quarter of 2023 were $1,146 million, an increase of 7%, or $77 million, compared to the third quarter of 2022. In local currency terms, revenues were flat compared to the third quarter of 2022. Revenues in the third quarter of 2023 included $15 million from a positive hedging impact, which is included in “Other” in the table below. Revenues in the third quarter of 2022 included $24 million from a positive hedging impact, which is included in “Other” in the table below.
Revenues by Major Products and Activities
The following table presents revenues for our Europe segment by major products and activities for the three months ended September 30, 2023 and 2022:
|
|
|
Three months ended |
|
Percentage |
||||
|
|
|
2023 |
|
2022 |
|
2023-2022 |
||
|
|
|
(U.S. $ in millions) |
|
|
||||
|
Generic products |
|
$ |
886 |
|
$ |
803 |
|
10% |
|
AJOVY |
|
|
41 |
|
|
30 |
|
36% |
|
COPAXONE |
|
|
55 |
|
|
63 |
|
(13%) |
|
Respiratory products |
|
|
61 |
|
|
62 |
|
(2%) |
|
Other |
|
|
104 |
|
|
111 |
|
(7%) |
|
Total |
|
$ |
1,146 |
|
$ |
1,069 |
|
7% |
|
|
|
|
|
|
|
|
|
|
Generic products revenues (including OTC and biosimilar products) in our Europe segment in the third quarter of 2023, increased by 10% to $886 million, compared to the third quarter of 2022. In local currency terms, revenues increased by 2%, mainly due to higher volumes of generic products and OTC price increases.
AJOVY revenues in our Europe segment in the third quarter of 2023 increased by 36% in U.S. dollars. In local currency terms revenues increased by 28% to $41 million, compared to $30 million in the third quarter of 2022. This increase was mainly due to growth in the European countries in which AJOVY had previously been launched.
COPAXONE revenues in our Europe segment in the third quarter of 2023 decreased by 13% to $55 million, compared to the third quarter of 2022. In local currency terms, revenues decreased by 19%, due to price reductions and a decline in volume resulting from competing glatiramer acetate products.
Respiratory products revenues in our Europe segment in the third quarter of 2023 decreased by 2% to $61 million compared to the third quarter of 2022. In local currency terms, revenues decreased by 9% compared to the third quarter of 2022, mainly due to lower volumes.
Europe Gross Profit
Gross profit from our Europe segment in the third quarter of 2023 was $648 million, an increase of 2% compared to $634 million in the third quarter of 2022.
Gross profit margin for our Europe segment in the third quarter of 2023 decreased to 56.6%, compared to 59.3% in the third quarter of 2022. This decrease was mainly due to higher cost of goods sold, mainly driven by higher costs due to inflationary and other macroeconomic pressures.
Europe Profit
Profit from our Europe segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.
Profit from our Europe segment in the third quarter of 2023 was $338 million, a decrease of 6%, compared to $360 million in the third quarter of 2022. This decrease was mainly due to higher operating expenses partially driven by exchange rate fluctuations, as described above.
International Markets Segment
Our International Markets segment includes all countries in which we operate other than those in our North America and Europe segments. As part of a recent shift in executive management responsibilities, commencing January 1, 2024, Canada will be reported under our International Markets segment and will no longer be included as part of our North America segment.
The following table presents revenues, expenses and profit for our International Markets segment for the three months ended September 30, 2023 and 2022:
|
|
Three months ended September 30, |
|||||
|
|
2023 |
|
2022 |
|||
|
|
(U.S. $ in millions / % of Segment Revenues) |
|||||
|
Revenues |
$ |
485 |
100% |
$ |
475 |
100% |
|
Gross profit |
|
261 |
53.8% |
|
252 |
53.0% |
|
R&D expenses |
|
23 |
4.8% |
|
15 |
3.2% |
|
S&M expenses |
|
102 |
21.0% |
|
97 |
20.5% |
|
G&A expenses |
|
27 |
5.6% |
|
30 |
6.2% |
|
Other income |
|
(2) |
§ |
|
(2) |
§ |
|
Segment profit* |
$ |
111 |
22.8% |
$ |
112 |
23.5% |
|
__________ |
|
|
|
|
|
|
|
* Segment profit does not include amortization and certain other items. |
||||||
Revenues from our International Markets segment in the third quarter of 2023 were $485 million, an increase of 2% compared to the third quarter of 2022. In local currency terms, revenues increased by 20% compared to the third quarter of 2022, mainly due to higher revenues from generic products in most markets, partially offset by regulatory price reductions and generic competition to off-patented products in Japan.
In the third quarter of 2023, revenues were negatively impacted by exchange rate fluctuations of $83 million, net of hedging effects, compared to the third quarter of 2022. Revenues in the third quarter of 2023 included a positive hedging impact of $6 million compared to a positive hedging impact of $4 million in the third quarter of 2022, which are included in “Other” in the table below.
Revenues by Major Products and Activities
The following table presents revenues for our International Markets segment by major products and activities for the three months ended September 30, 2023 and 2022:
|
|
|
|
|
|
||||
|
|
|
Three months ended |
|
Percentage |
||||
|
|
|
2023 |
|
2022 |
|
2023-2022 |
||
|
|
|
(U.S. $ in millions) |
|
|
||||
|
Generic products |
|
$ |
381 |
|
$ |
393 |
|
(3%) |
|
AJOVY |
|
|
12 |
|
|
6 |
|
113% |
|
COPAXONE |
|
|
10 |
|
|
9 |
|
10% |
|
Other |
|
|
82 |
|
|
67 |
|
21% |
|
Total |
|
$ |
485 |
|
$ |
475 |
|
2% |
|
|
||||||||
Generic products revenues in our International Markets segment were $381 million in the third quarter of 2023 compared to $393 million in the third quarter of 2022. In local currency terms, revenues increased by 17% compared to the third quarter of 2022, mainly due to higher revenues in most markets, largely driven by price increases largely as a result of higher costs due to inflationary pressure, partially offset by regulatory price reductions and generic competition to off-patented products in Japan.
AJOVY was launched in certain markets in our International Markets segment, including in Japan in August 2021. We are moving forward with plans to launch AJOVY in other markets. AJOVY revenues in our International Markets segment in the third quarter of 2023 were $12 million, compared to $6 million in the third quarter of 2022.
COPAXONE revenues in our International Markets segment in the third quarter of 2023 were $10 million compared to $9 million in the third quarter of 2022.
AUSTEDO was launched in China and Israel during 2021 and in Brazil in 2022, for the treatment of chorea associated with Huntington’s disease and for the treatment of tardive dyskinesia. We continue with additional submissions in various other markets.
International Markets Gross Profit
Gross profit from our International Markets segment in the third quarter of 2023 was $261 million, an increase of 4% compared to $252 million in the third quarter of 2022.
Gross profit margin for our International Markets segment in the third quarter of 2023 increased to 53.8%, compared to 53.0% in the third quarter of 2022. This increase was mainly due to price increases largely as a result of inflationary pressures and a favorable product mix, partially offset by regulatory price reductions and generic competition to off-patented products in Japan, as well as higher costs due to inflationary and other macroeconomic pressures.
International Markets Profit
Profit from our International Markets segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.
Profit from our International Markets segment in the third quarter of 2023 was $111 million, a decrease of 1%, compared to $112 million in the third quarter of 2022.
Other Activities
We have other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. Our other activities are not included in our North America, Europe or International Markets segments described above.
R evenues from other activities in the third quarter of 2023 were $217 million, a decrease of 10% in U.S. dollars. In local currency terms revenues decreased by 12% compared to the third quarter of 2022.
API sales to third parties in the third quarter of 2023 were $131 million, a decrease of 12% in both U.S. dollars and local currency terms, compared to the third quarter of 2022.
Outlook for 2023 Non-GAAP Results
|
$ billions, except |
November 2023 |
August 2023 Outlook |
February 2023 Outlook |
2022 Actual |
||||||||
|
Revenues* |
$15.1 – $15.5 |
$15.0 – $15.4 |
$14.8 – $15.4 |
$14.9 |
||||||||
|
COPAXONE ($m)* |
~550 |
~500 |
~500 |
691 |
||||||||
|
AUSTEDO ($m)* |
~1,200 |
~1,200 |
~1,200 |
971 |
||||||||
|
AJOVY ($m)* |
~400 |
~400 |
~400 |
377 |
||||||||
|
Operating Income |
4.0 – 4.4 |
4.0 – 4.4 |
4.0 – 4.4 |
4.1 |
||||||||
|
Adjusted EBITDA |
4.5 – 4.9 |
4.5 – 4.9 |
4.5 – 4.9 |
4.6 |
||||||||
|
Finance Expenses ($m) |
~1,000 |
~1,000 |
~1,000 |
904 |
||||||||
|
Tax Rate |
12% – 15% |
14% – 17% |
14% – 17% |
11.7% |
||||||||
|
Diluted EPS ($) |
2.25 – 2.55 |
2.25 – 2.55 |
2.25 – 2.55 |
2.52 |
||||||||
|
Free Cash Flow** |
1.7 – 2.1 |
1.7 – 2.1 |
1.7 – 2.1 |
2.2 |
||||||||
|
CAPEX* |
0.5 |
0.5 |
0.5 |
0.5 |
||||||||
|
Foreign Exchange |
Volatile swings in FX can negatively impact revenue and income |
|||||||||||
Revenue, operating income, adjusted EBITDA, diluted EPS and free cash flow outlook range does not take into account execution and upfront milestone for Anti-TL1A under collaboration agreement with Sanofi.
* Revenues and CAPEX presented on a GAAP basis.
** Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.
Conference Call
Teva will host a conference call and live webcast including a slide presentation on November 8, 2023, at 8:00 a.m. ET to discuss its third quarter 2023 results and overall business environment. A question & answer session will follow.
In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.
A live webcast of the call will be available on Teva’s website at: ir.tevapharm.com.
Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva’s website.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative medicines and biopharmaceutical products. Learn more at http://www.tevapharm.com.
Some amounts in this press release may not add up due to rounding. All percentages have been calculated using unrounded amounts.
Non-GAAP Financial Measures
This press release contains certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures, including, but not limited to, non-GAAP operating income, non-GAAP operating margin, non-GAAP gross profit, non-GAAP gross profit margin, Adjusted EBITDA, free cash flow, non-GAAP tax rate, non-GAAP net income (loss) attributable to Teva and non-GAAP diluted EPS, are presented in order to facilitate investors' understanding of our business. We utilize certain non-GAAP financial measures to evaluate performance, in conjunction with other performance metrics. The following are examples of how we utilize the non-GAAP measures: our management and board of directors use the non-GAAP measures to evaluate our operational performance, to compare against work plans and budgets, and ultimately to evaluate the performance of management; our annual budgets are prepared on a non-GAAP basis; and senior management’s annual compensation is derived, in part, using these non-GAAP measures. See the attached tables for a reconciliation of the GAAP results to the adjusted non-GAAP measures. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. We are not providing forward looking guidance for GAAP reported financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measure because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items including, but not limited to, the amortization of purchased intangible assets, legal settlements and loss contingencies, impairment of long-lived assets and goodwill impairment, without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to:
- our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; concentration of our customer base and commercial alliances among our customers; delays in launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to develop and commercialize biopharmaceutical products; competition for our innovative medicines, including AUSTEDO, AJOVY and COPAXONE; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; our ability to successfully launch and execute our new Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; and the effectiveness of our patents and other measures to protect our intellectual property rights, including any potential challenges to our Orange Book patent listings in the U.S.;
- our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
- our business and operations in general, including: the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; the widespread outbreak of an illness or any other communicable disease, or any other public health crisis; effectiveness of our optimization efforts; our ability to attract, hire, integrate and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;
- compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; increased legal and regulatory action in connection with public concern over the abuse of opioid medications; our ability to timely make payments required under our nationwide opioids settlement agreement and provide our generic version of Narcan® (naloxone hydrochloride nasal spray) in the amounts and at the times required under the terms of such agreement; scrutiny from competition and pricing authorities around the world, including our ability to comply with and operate under our deferred prosecution agreement with the U.S. Department of Justice; potential liability for intellectual property right infringement; product liability claims; failure to comply with complex Medicare, Medicaid and other government programs reporting and payment obligations; compliance with anti-corruption, sanctions and trade control laws; environmental risks; and the impact of ESG issues;
- the impact of the state of war declared in Israel and the military activity in the region, including the risk of disruptions to our operations and facilities, such as our manufacturing and R&D facilities, located in Israel, the impact of our employees who are military reservists being called to active military duty, and the impact of the war on the economic, social and political stability of Israel;
- other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our long-lived assets; the impact of geopolitical conflicts including the state of war declared in Israel and the conflict between Russia and Ukraine; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;
and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the third quarter of 2023 and in our Annual Report on Form 10-K for the year ended December 31, 2022, including in the sections captioned "Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
For an accessible version of this Press Release, please visit www.tevapharm.com
| Consolidated Statements of Income | ||||||||
| (U.S. dollars in millions, except share and per share data) | ||||||||
| (Unaudited) | ||||||||
| Three months ended | Nine months ended | |||||||
| September 30, | September 30, | |||||||
|
2023 |
|
2022 |
|
2023 |
|
2022 |
||
| Net revenues |
3,850 |
3,595 |
11,389 |
11,041 |
||||
| Cost of sales |
1,999 |
1,926 |
6,159 |
5,839 |
||||
| Gross profit |
1,851 |
1,669 |
5,230 |
5,203 |
||||
| Research and development expenses |
253 |
175 |
726 |
628 |
||||
| Selling and marketing expenses |
576 |
539 |
1,726 |
1,716 |
||||
| General and administrative expenses |
268 |
283 |
870 |
892 |
||||
| Intangible assets impairments |
47 |
24 |
289 |
223 |
||||
| Other asset impairments, restructuring and other items |
46 |
36 |
241 |
282 |
||||
| Goodwill impairment |
- |
- |
700 |
745 |
||||
| Legal settlements and loss contingencies |
314 |
195 |
1,009 |
2,048 |
||||
| Other income |
(9) |
(2) |
(43) |
(88) |
||||
| Operating income (loss) |
355 |
419 |
(289) |
(1,244) |
||||
| Financial expenses, net |
280 |
252 |
808 |
721 |
||||
| Income (loss) before income taxes |
75 |
166 |
(1,097) |
(1,964) |
||||
| Income taxes (benefit) |
(12) |
107 |
(48) |
(792) |
||||
| Share in (profits) losses of associated companies, net | § |
1 |
(1) |
(20) |
||||
| Net income (loss) |
88 |
58 |
(1,048) |
(1,152) |
||||
| Net income (loss) attributable to non-controlling interests |
8 |
3 |
(60) |
(21) |
||||
| Net income (loss) attributable to Teva |
80 |
56 |
(988) |
(1,132) |
||||
| Earnings (loss) per share attributable to Teva: | Basic ($) |
0.07 |
0.05 |
(0.88) |
(1.02) |
|||
| Diluted ($) |
0.07 |
0.05 |
(0.88) |
(1.02) |
||||
| Weighted average number of shares (in millions): | Basic |
1,121 |
1,111 |
1,119 |
1,109 |
|||
| Diluted |
1,135 |
1,119 |
1,119 |
1,109 |
||||
| Non-GAAP net income attributable to Teva for diluted earnings per share:* |
677 |
658 |
1,763 |
2,021 |
||||
| Non-GAAP earnings per share attributable to Teva:* | Diluted ($) |
0.60 |
0.59 |
1.56 |
1.81 |
|||
| Non-GAAP average number of shares (in millions): | Diluted |
1,135 |
1,119 |
1,131 |
1,114 |
|||
| Amounts may not add up due to rounding. | ||||||||
| * See reconciliation attached. | ||||||||
| CONSOLIDATED BALANCE SHEETS | ||||||
| (U.S. dollars in millions, except for share data) | ||||||
| (Unaudited) | ||||||
| September 30, | December 31, | |||||
|
2023 |
2022 |
|||||
| ASSETS | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ |
2,249 |
$ |
2,801 |
||
| Accounts receivables, net of allowance for credit losses of $86 million and $91 million as of September 30, 2023 and December 31, 2022 |
3,385 |
3,696 |
||||
| Inventories |
4,051 |
3,833 |
||||
| Prepaid expenses |
1,168 |
1,162 |
||||
| Other current assets |
520 |
549 |
||||
| Assets held for sale |
51 |
10 |
||||
| Total current assets |
11,425 |
12,051 |
||||
| Deferred income taxes |
1,748 |
1,453 |
||||
| Other non-current assets |
477 |
441 |
||||
| Property, plant and equipment, net |
5,622 |
5,739 |
||||
| Operating lease right-of-use assets, net |
406 |
419 |
||||
| Identifiable intangible assets, net |
5,525 |
6,270 |
||||
| Goodwill |
16,885 |
17,633 |
||||
| Total assets | $ |
42,088 |
$ |
44,006 |
||
| LIABILITIES AND EQUITY | ||||||
| Current liabilities: | ||||||
| Short-term debt | $ |
1,479 |
$ |
2,109 |
||
| Sales reserves and allowances |
3,351 |
3,750 |
||||
| Accounts payables |
2,280 |
1,887 |
||||
| Employee-related obligations |
530 |
566 |
||||
| Accrued expenses |
2,741 |
2,151 |
||||
| Other current liabilities |
1,011 |
1,005 |
||||
| Total current liabilities |
11,394 |
11,469 |
||||
| Long-term liabilities: | ||||||
| Deferred income taxes |
544 |
548 |
||||
| Other taxes and long-term liabilities |
3,818 |
3,847 |
||||
| Senior notes and loans |
18,495 |
19,103 |
||||
| Operating lease liabilities |
324 |
349 |
||||
| Total long-term liabilities |
23,182 |
23,846 |
||||
| Equity: | ||||||
| Teva shareholders’ equity: |
6,929 |
7,897 |
||||
| Non-controlling interests |
582 |
794 |
||||
| Total equity |
7,512 |
8,691 |
||||
| Total liabilities and equity | $ |
42,088 |
$ |
44,006 |
||
|
Amounts may not add up due to rounding. |
||||||
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | |||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
| (U.S. dollars in millions) | |||||||
| (Unaudited) | |||||||
| Three months ended | Nine months ended | ||||||
| September 30, | September 30, | ||||||
|
2023 |
2022 |
2023 |
2022 |
||||
| Operating activities: | |||||||
| Net income (loss) | $ |
88 |
58 |
$ |
(1,048) |
(1,152) |
|
| Adjustments to reconcile net income (loss) to net cash provided by operations: | |||||||
| Depreciation and amortization |
283 |
321 |
887 |
1,002 |
|||
| Impairment of goodwill, long-lived assets and assets held for sale |
48 |
28 |
1,010 |
1,002 |
|||
| Net change in operating assets and liabilities |
(238) |
93 |
(398) |
1,007 |
|||
| Deferred income taxes – net and uncertain tax positions |
(199) |
44 |
(349) |
(1,214) |
|||
| Stock-based compensation |
31 |
26 |
93 |
88 |
|||
| Other items |
(3) |
(40) |
20 |
(117) |
|||
| Net loss (gain) from investments and from sale of long lived assets |
(5) |
13 |
(31) |
1 |
|||
| Net cash provided by (used in) operating activities |
5 |
543 |
184 |
617 |
|||
| Investing activities: | |||||||
| Beneficial interest collected in exchange for securitized trade receivables |
362 |
262 |
1,056 |
854 |
|||
| Purchases of property, plant and equipment and intangible assets |
(149) |
(122) |
(407) |
(406) |
|||
| Proceeds from sale of business and long lived assets |
10 |
2 |
68 |
45 |
|||
| Acquisition of businesses, net of cash acquired |
- |
- |
- |
(7) |
|||
| Purchases of investments and other assets . |
(38) |
2 |
(44) |
(2) |
|||
| Other investing activities |
(1) |
3 |
(6) |
4 |
|||
| Net cash provided by (used in) investing activities |
184 |
147 |
667 |
488 |
|||
| Financing activities: | |||||||
| Repayment of senior notes and loans and other long term liabilities |
(1,000) |
(365) |
(4,152) |
(661) |
|||
| Proceeds from senior notes, net of issuance costs |
- |
- |
2,451 |
- |
|||
| Proceeds from short term debt |
700 |
- |
700 |
- |
|||
| Repayment of short term debt |
(200) |
- |
(200) |
- |
|||
| Other financing activities |
(76) |
(75) |
(136) |
(115) |
|||
| Net cash provided by (used in) financing activities |
(576) |
(439) |
(1,337) |
(776) |
|||
| Translation adjustment on cash and cash equivalents |
(33) |
(84) |
(98) |
(269) |
|||
| Net change in cash, cash equivalents and restricted cash |
(420) |
167 |
(584) |
60 |
|||
| Balance of cash, cash equivalents and restricted cash at beginning of period |
2,670 |
2,091 |
2,834 |
2,198 |
|||
| Balance of cash, cash equivalents and restricted cash at end of period | $ |
2,250 |
2,258 |
2,250 |
2,258 |
||
| Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets: | |||||||
| Cash and cash equivalents |
2,249 |
2,225 |
2,249 |
2,225 |
|||
| Restricted cash included in other current assets . . |
1 |
33 |
1 |
33 |
|||
| Total cash, cash equivalents and restricted cash shown in the statement of cash flows |
2,250 |
2,258 |
2,250 |
2,258 |
|||
| Non-cash financing and investing activities: | |||||||
| Beneficial interest obtained in exchange for securitized accounts receivables | $ |
376 |
293 |
1,090 |
883 |
||
| Dividend declared to non-controlling interests | $ |
67 |
- |
67 |
- |
||
| Amounts may not add up due to rounding | |||||||
| Reconciliation of gross profit to Non-GAAP gross profit | ||||||||
| Three months ended | Nine months ended | |||||||
| September 30, | September 30, | |||||||
| ($ in millions) |
2023 |
2022 |
|
2023 |
2022 |
|||
| Gross profit | $ |
1,851 |
1,669 |
$ |
5,230 |
5,203 |
||
| Gross profit margin |
48.1% |
46.4% |
45.9% |
47.1% |
||||
| Increase (decrease) for excluded items: | ||||||||
| Amortization of purchased intangible assets |
130 |
145 |
420 |
513 |
||||
| Costs related to regulatory actions taken in facilities |
1 |
2 |
3 |
6 |
||||
| Equity compensation |
5 |
5 |
15 |
16 |
||||
| Accelerated depreciation |
25 |
44 |
74 |
77 |
||||
| Other non-GAAP items* |
48 |
41 |
137 |
136 |
||||
| Non-GAAP gross profit | $ |
2,060 |
1,906 |
$ |
5,878 |
5,951 |
||
| Non-GAAP gross profit margin** |
53.5% |
53.0% |
51.6% |
53.9% |
||||
| * Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, primarily related to the rationalization of our plants, certain inventory write-offs and other unusual events. | ||||||||
| ** Non-GAAP gross profit margin is non-GAAP gross profit as a percentage of revenue. | ||||||||
| Reconciliation of operating income (loss) to Non-GAAP operating income (loss) | |||||||
| Three months ended | Nine months ended | ||||||
| September 30, | September 30, | ||||||
| ($ in millions) |
2023 |
2022 |
|
2023 |
2022 |
||
| Operating income (loss) | ($) |
355 |
419 |
($) |
(289) |
(1,244) |
|
| Operating margin |
9.2% |
11.6% |
(2.5%) |
(11.3%) |
|||
| Increase (decrease) for excluded items: | |||||||
| Amortization of purchased intangible assets |
145 |
165 |
471 |
576 |
|||
| Legal settlements and loss contingencies |
314 |
195 |
1,009 |
2,048 |
|||
| Goodwill impairment |
- |
- |
700 |
745 |
|||
| Impairment of long-lived assets |
48 |
28 |
310 |
257 |
|||
| Restructuring costs |
27 |
25 |
93 |
117 |
|||
| Costs related to regulatory actions taken in facilities |
1 |
2 |
3 |
6 |
|||
| Equity compensation |
31 |
26 |
93 |
88 |
|||
| Contingent consideration |
16 |
6 |
106 |
100 |
|||
| Loss (gain) on sale of business |
(5) |
§ |
(3) |
(31) |
|||
| Accelerated depreciation |
25 |
45 |
74 |
78 |
|||
| Other non-GAAP items* |
63 |
67 |
249 |
268 |
|||
| Non-GAAP operating income (loss) | ($) |
1,020 |
977 |
($) |
2,816 |
3,010 |
|
| Non-GAAP operating margin** | ($) |
26.5% |
27.2% |
($) |
24.7% |
27.3% |
|
| * Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, primarily related to the rationalization of our plants, certain inventory write-offs, material litigation fees and other unusual events. | ||||||||
| ** Non-GAAP operating margin is Non-GAAP operating income as a percentage of revenues. | ||||||||
| § Represents an amount less than $0.5 million. | ||||||||
| Reconciliation of net income (loss) attributable to Teva | |||||||
| to Non-GAAP net income (loss) attributable to Teva | |||||||
| Three months ended | Nine months ended | ||||||
| September 30, | September 30, | ||||||
| ($ in millions except per share amounts) |
2023 |
2022 |
|
2023 |
2022 |
||
| Net income (Loss) attributable to Teva |
($) |
80 |
56 |
($) |
(988) |
(1,132) |
|
| Increase (decrease) for excluded items: |
|
|
|||||
| Amortization of purchased intangible assets |
|
145 |
165 |
|
471 |
576 |
|
| Legal settlements and loss contingencies |
|
314 |
195 |
|
1,009 |
2,048 |
|
| Goodwill impairment |
|
- |
- |
|
700 |
745 |
|
| Impairment of long-lived assets |
|
48 |
28 |
|
310 |
257 |
|
| Restructuring costs |
|
27 |
25 |
|
93 |
117 |
|
| Costs related to regulatory actions taken in facilities |
|
1 |
2 |
|
3 |
6 |
|
| Equity compensation |
|
31 |
26 |
|
93 |
88 |
|
| Contingent consideration |
|
16 |
6 |
|
106 |
100 |
|
| Loss (Gain) on sale of business |
|
(5) |
0 |
|
(3) |
(31) |
|
| Accelerated depreciation |
|
25 |
45 |
|
74 |
78 |
|
| Financial expenses |
|
14 |
14 |
|
53 |
48 |
|
| Share in profits (losses) of associated companies – net |
|
- |
- |
|
- |
(22) |
|
| Items attributable to non-controlling interests |
|
(1) |
(4) |
|
(91) |
(54) |
|
| Other non-GAAP items* |
|
63 |
67 |
|
249 |
268 |
|
| Corresponding tax effects and unusual tax items |
|
(80) |
33 |
|
(315) |
(1,072) |
**** |
| Non-GAAP net income attributable to Teva |
($) |
677 |
658 |
($) |
1,762 |
2,021 |
|
| Non-GAAP tax rate** |
|
9.0% |
10.0% |
|
13.0% |
12.0% |
|
| GAAP diluted earnings (loss) per share attributable to Teva |
($) |
0.07 |
0.05 |
($) |
(0.88) |
(1.02) |
|
| EPS difference*** |
|
0.52 |
0.54 |
|
2.44 |
2.83 |
|
| Non-GAAP diluted EPS attributable to Teva*** |
($) |
0.60 |
0.59 |
($) |
1.56 |
1.81 |
|
| Non-GAAP average number of shares (in millions)*** |
1,135 |
1,119 |
1,131 |
1,114 |
|||
| * | Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, primarily related to the rationalization of our plants, certain inventory write-offs, material litigation fees and other unusual events. | ||||||||
| ** | Non-GAAP tax rate is tax expenses (benefit) excluding the impact of non-GAAP tax adjustments presented above as a percentage of income (loss) before income taxes excluding the impact of non-GAAP adjustments presented above. | ||||||||
| *** | EPS difference and diluted non-GAAP EPS are calculated by dividing our non-GAAP net income attributable to Teva by our non-GAAP diluted weighted average number of shares. | ||||||||
| **** | Includes a portion of the realization of a loss related to an investment in one of our U.S. subsidiaries as well as corresponding tax effects on non-GAAP items | ||||||||
| Reconciliation of net income (loss) to adjusted EBITDA | ||||||||
| Three months ended | Nine months ended | |||||||
| September 30, | September 30, | |||||||
| ($ in millions) | $ |
2023 |
2022 |
|
|
2023 |
2022 |
|
| Net income (loss) |
88 |
58 |
$ |
(1,048) |
(1,152) |
|||
| Increase (decrease) for excluded items: | ||||||||
| Financial expenses |
280 |
252 |
808 |
721 |
||||
| Income taxes |
(12) |
107 |
(48) |
(792) |
||||
| Share in profits (losses) of associated companies –net | § |
1 |
(1) |
(20) |
||||
| Depreciation |
139 |
156 |
416 |
426 |
||||
| Amortization |
145 |
165 |
471 |
576 |
||||
| EBITDA |
639 |
740 |
599 |
(241) |
||||
| Legal settlements and loss contingencies |
314 |
195 |
1,009 |
2,048 |
||||
| Goodwill impairment |
- |
- |
700 |
745 |
||||
| Impairment of long lived assets |
48 |
28 |
310 |
257 |
||||
| Restructuring costs |
27 |
25 |
93 |
117 |
||||
| Costs related to regulatory actions taken in facilities |
1 |
2 |
3 |
6 |
||||
| Equity compensation |
31 |
26 |
93 |
88 |
||||
| Contingent consideration |
16 |
6 |
106 |
100 |
||||
| Loss (gain) on sale of business |
(5) |
§ |
(3) |
(31) |
||||
| Other non-GAAP items * |
63 |
68 |
249 |
268 |
||||
| Adjusted EBITDA | $ |
1,134 |
1,089 |
$ |
3,158 |
3,358 |
||
| *Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, primarily related to the rationalization of our plants, certain inventory write-offs, material litigation fees and other unusual events. | ||||||||
| § Represents an amount less than $0.5 million. | ||||||||
| Segment Information | |||||||||||||||||
| North America | Europe | International Markets | |||||||||||||||
| Three months ended September 30, | Three months ended September 30, | Three months ended September 30, | |||||||||||||||
|
2023 |
|
2022 |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
|||||||
| (U.S. $ in millions) | (U.S. $ in millions) | (U.S. $ in millions) | |||||||||||||||
| Revenues | $ |
2,002 |
$ |
1,809 |
$ |
1,146 |
$ |
1,069 |
$ |
485 |
$ |
475 |
|||||
| Gross profit |
1,093 |
942 |
648 |
634 |
261 |
252 |
|||||||||||
| R&D expenses |
163 |
111 |
62 |
44 |
23 |
15 |
|||||||||||
| S&M expenses |
257 |
232 |
184 |
169 |
102 |
97 |
|||||||||||
| G&A expenses |
98 |
122 |
66 |
61 |
27 |
30 |
|||||||||||
| Other income |
(2) |
§ | § | § |
(2) |
(2) |
|||||||||||
| Segment profit | $ |
577 |
$ |
477 |
$ |
338 |
$ |
360 |
$ |
111 |
$ |
112 |
|||||
| § Represents an amount less than $0.5 million. | |||||||||||||||||
| Segment Information | |||||||||||||||||
| North America | Europe | International Markets | |||||||||||||||
| Nine months ended September 30, | Nine months ended September 30, | Nine months ended September 30, | |||||||||||||||
|
2023 |
|
2022 |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
|||||||
| (U.S. $ in millions) | (U.S. $ in millions) | (U.S. $ in millions) | |||||||||||||||
| Revenues | $ |
5,759 |
$ |
5,450 |
$ |
3,493 |
$ |
3,396 |
$ |
1,456 |
$ |
1,422 |
|||||
| Gross profit |
2,950 |
2,841 |
1,943 |
2,031 |
778 |
780 |
|||||||||||
| R&D expenses |
478 |
401 |
168 |
157 |
64 |
54 |
|||||||||||
| S&M expenses |
743 |
733 |
565 |
561 |
310 |
293 |
|||||||||||
| G&A expenses |
306 |
361 |
196 |
183 |
87 |
89 |
|||||||||||
| Other income |
(6) |
(12) |
(2) |
(1) |
(31) |
(43) |
|||||||||||
| Segment profit | $ |
1,429 |
$ |
1,359 |
$ |
1,017 |
$ |
1,130 |
$ |
348 |
$ |
386 |
|||||
| Reconciliation of our segment profit | ||||||
| to consolidated income before income taxes | ||||||
| Three months ended | ||||||
| September 30, | ||||||
|
2023 |
2022 |
|||||
| (U.S.$ in millions) | ||||||
| North America profit | $ |
577 |
$ |
477 |
||
| Europe profit |
338 |
360 |
||||
| International Markets profit |
111 |
112 |
||||
| Total reportable segment profit |
1,025 |
949 |
||||
| Profit of other activities |
(5) |
29 |
||||
|
1,020 |
977 |
|||||
| Amounts not allocated to segments: | ||||||
| Amortization |
145 |
165 |
||||
| Other asset impairments, restructuring and other items |
46 |
36 |
||||
| Intangible asset impairments |
47 |
24 |
||||
| Legal settlements and loss contingencies |
314 |
195 |
||||
| Other unallocated amounts |
112 |
139 |
||||
| Consolidated operating income (loss) |
355 |
419 |
||||
| Financial expenses - net |
280 |
252 |
||||
| Consolidated income (loss) before income taxes | $ |
75 |
$ |
166 |
||
| Reconciliation of our segment profit | ||||||
| to consolidated income before income taxes | ||||||
| Nine months ended | ||||||
| September 30, | ||||||
|
2023 |
2022 |
|||||
| (U.S.$ in millions) | ||||||
| North America profit | $ |
1,429 |
$ |
1,359 |
||
| Europe profit |
1,017 |
1,130 |
||||
| International Markets profit |
348 |
386 |
||||
| Total reportable segment profit |
2,794 |
2,875 |
||||
| Profit of other activities |
22 |
135 |
||||
| Total segment profit |
2,816 |
3,010 |
||||
| Amounts not allocated to segments: | ||||||
| Amortization |
471 |
576 |
||||
| Other asset impairments, restructuring and other items |
241 |
282 |
||||
| Goodwill impairment |
700 |
745 |
||||
| Intangible asset impairments |
289 |
223 |
||||
| Legal settlements and loss contingencies |
1,009 |
2,048 |
||||
| Other unallocated amounts |
394 |
379 |
||||
| Consolidated operating income (loss) |
(289) |
(1,244) |
||||
| Financial expenses - net |
808 |
721 |
||||
| Consolidated income (loss) before income taxes | $ |
(1,097) |
$ |
(1,964) |
||
| Segment revenues by major products and activities | ||||||||
| Three months ended | ||||||||
| September 30, | Percentage Change |
|||||||
|
2023 |
2022 |
2022-2023 | ||||||
| (U.S.$ in millions) | ||||||||
| North America segment |
|
|||||||
| Generic products | $ |
929 |
$ |
806 |
15% |
|||
| AJOVY |
61 |
57 |
8% |
|||||
| AUSTEDO |
339 |
260 |
30% |
|||||
| BENDEKA/TREANDA |
57 |
77 |
(26%) |
|||||
| COPAXONE |
103 |
105 |
(2%) |
|||||
| Anda |
367 |
371 |
(1%) |
|||||
| Other |
146 |
133 |
10% |
|||||
| Total |
2,002 |
1,809 |
11% |
|||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Three months ended |
|
|||||||
| September 30, |
Percentage |
|||||||
|
2023 |
2022 |
2022-2023 |
||||||
| (U.S.$ in millions) |
|
|||||||
| Europe segment |
|
|||||||
| Generic products | $ |
886 |
$ |
803 |
10% |
|||
| AJOVY |
41 |
30 |
36% |
|||||
| COPAXONE |
55 |
63 |
(13%) |
|||||
| Respiratory products |
61 |
62 |
(2%) |
|||||
| Other |
104 |
111 |
(7%) |
|||||
| Total |
1,146 |
1,069 |
7% |
|||||
|
|
||||||||
|
|
||||||||
| Three months ended |
|
|||||||
| September 30, |
Percentage |
|||||||
|
2023 |
2022 |
2022-2023 |
||||||
| (U.S.$ in millions) |
|
|||||||
| International Markets segment |
|
|||||||
| Generic products | $ |
381 |
$ |
393 |
(3%) |
|||
| AJOVY |
12 |
6 |
113% |
|||||
| COPAXONE |
10 |
9 |
10% |
|||||
| Other |
82 |
67 |
21% |
|||||
| Total |
485 |
475 |
2% |
|||||
| Segment revenues by major products and activities | ||||||||
| Nine months ended | ||||||||
| September 30, | Percentage Change |
|||||||
|
2023 |
2022 |
2022-2023 | ||||||
| (U.S.$ in millions) | ||||||||
| North America segment | ||||||||
| Generic products | $ |
2,722 |
$ |
2,731 |
0% |
|||
| AJOVY |
168 |
142 |
18% |
|||||
| AUSTEDO |
817 |
618 |
32% |
|||||
| BENDEKA / TREANDA |
188 |
241 |
(22%) |
|||||
| COPAXONE |
242 |
285 |
(15%) |
|||||
| Anda |
1,183 |
1,021 |
16% |
|||||
| Other |
439 |
411 |
7% |
|||||
| Total |
5,759 |
5,450 |
6% |
|||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Nine months ended |
|
|||||||
| September 30, |
Percentage |
|||||||
|
2023 |
2022 |
2022-2023 |
||||||
| (U.S.$ in millions) |
|
|||||||
| Europe segment |
|
|||||||
| Generic products | $ |
2,727 |
$ |
2,552 |
7% |
|||
| AJOVY |
115 |
90 |
28% |
|||||
| COPAXONE |
174 |
207 |
(16%) |
|||||
| Respiratory products |
195 |
198 |
(2%) |
|||||
| Other |
282 |
349 |
(19%) |
|||||
| Total |
3,493 |
3,396 |
3% |
|||||
|
|
||||||||
|
|
||||||||
| Nine months ended |
|
|||||||
| September 30, |
Percentage |
|||||||
|
2023 |
2022 |
2022-2023 |
||||||
| (U.S.$ in millions) |
|
|||||||
| International Markets segment |
|
|||||||
| Generic products | $ |
1,175 |
$ |
1,175 |
0% |
|||
| AJOVY |
31 |
22 |
40% |
|||||
| COPAXONE |
32 |
29 |
9% |
|||||
| Other |
219 |
195 |
12% |
|||||
| Total |
1,456 |
1,422 |
2% |
|||||
| Free cash flow reconciliation | |||||
| (Unaudited) | |||||
| Three months ended September 30, | |||||
|
2023 |
2022 |
||||
| (U.S. $ in millions) | |||||
| Net cash provided by (used in) operating activities |
5 |
543 |
|||
| Beneficial interest collected in exchange for securitized trade receivables |
362 |
262 |
|||
| Purchases of property, plant and equipment and intangible assets |
(149) |
(122) |
|||
| Proceeds from sale of business and long lived assets |
10 |
2 |
|||
| Free cash flow | $ |
229 |
$ |
685 |
|
| Free cash flow reconciliation | |||||
| (Unaudited) | |||||
| Nine months ended September 30, | |||||
|
2023 |
2022 |
||||
| (U.S. $ in millions) | |||||
| Net cash provided by (used in) operating activities |
184 |
617 |
|||
| Beneficial interest collected in exchange for securitized trade receivables |
1,056 |
854 |
|||
| Purchases of property, plant and equipment and intangible assets |
(407) |
(406) |
|||
| Proceeds from sale of business and long lived assets |
68 |
45 |
|||
| Acquisition of subsidiary, net of cash acquired |
- |
(7) |
|||
| Free cash flow | $ |
902 |
$ |
1,103 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20231108857866/en/
IR Contacts
Ran Meir
(215) 591-8912
Yael Ashman
+972 (3) 914 8262
Sanjeev Sharma
(267) 658-2700
PR Contacts
Kelley Dougherty
(973) 832-2810
Eden Klein
+972 (3) 906 2645
Source: Teva Pharmaceutical Industries Limited
